Hussain Mazhar, Akhtar Lubna
Dr. Mazhar Hussain, MBBS, M.Phil (Pharmacology), Department of Pharmacology & TherapeuticsSheikh Zayed Medical College, Rahim Yar Khan, Punjab, Pakistan.
Dr. Habib-Ur-Rehman, MBBS, MD, FCPS (Medicine), Department of Medicine, Sheikh Zayed Medical College & Hospital, Rahim Yar Khan, Punjab, Pakistan.
Pak J Med Sci. 2017 Jul-Aug;33(4):931-936. doi: 10.12669/pjms.334.12571.
NAFLD affecting up to 30% of the population globally. Drug treatment options are limited with disappointing results. The dietary supplementation in the form of green tea is another option. Our objective was toinvestigate the effect of Green tea extract (GTE) supplementation on various parameters innon-alcoholicfatty liver disease (NAFLD) patients.
This study was conducted Dept. of Medicineof Sheikh Zayed Medical College/Hospital, Rahim Yar Khan from 15 April 2016 to 15 July 2016. Eighty overweight, non diabeticand dyslipidemic patients of NAFLD, diagnosed on the basis of ultrasound and aminotransferases level were randomized for treatmentwith capsule GTE500mg (n=40)and capsule placebo (n=40) twice a day for twelve weeks. Anthropometric parameters, liver enzymes, inflammatory markers and liver ultrasound imaging were estimated by SPSS-16 pre and post treatment.
As compared to placebo, GTE caused a significant improvement in body weight (29.5±3.8 to 27.2±3.2 kg/m p=0.03), BMI (86±10.5 to 80±12.4 kg p=0.026), HOMA-IR(4.32±2.25 to 3.16± 1.6 p=0.0081) lipid profile (i.e. TC: L242.5±20.5 to 215.4±18.6 mg/dl p=0.005; TG: 175±22.6 to145±18 mg/dlp=0.003; LDL-C:155±12.5 to 140±16.7 mg/dl p=0.011; HDL-C: 36.8±6.7 to46.4±5.8 mg/dl p =0.001, Aminotransferases (i.e. ALT: 70.4±15.8to52.8±12.2 IU/L p=0.04; AST: 65.8±12.4 to 44.3± 8.5U/L p =0.002) and Inflammatory markers (hs-CRP: 3.14±0.58 to 2.18±0.32 p =0.023 Adiponectin: 8.46±1.02 to 10.55±3.42μg/ml p =0.003)GTE also caused a 67.5% regression of fatty liver changes on ultrasound as compared to placebo which is 25%only.
GTEtherapy resulted in significant improvement in metabolic, chemical, inflammatory and radiological parameters of non-alcoholic fatty liver disease patients who were non-diabetic anddyslipidemic.
非酒精性脂肪性肝病(NAFLD)影响着全球高达30%的人口。药物治疗选择有限且效果不佳。绿茶形式的膳食补充是另一种选择。我们的目的是研究绿茶提取物(GTE)补充剂对非酒精性脂肪性肝病(NAFLD)患者各项参数的影响。
本研究于2016年4月15日至2016年7月15日在拉希姆亚尔汗谢赫扎耶德医学院/医院内科进行。80名超重、非糖尿病且血脂异常的NAFLD患者,根据超声和转氨酶水平诊断,被随机分为两组,分别接受500毫克GTE胶囊(n = 40)和安慰剂胶囊(n = 40)治疗,每天两次,持续12周。在治疗前后通过SPSS - 16评估人体测量参数、肝酶、炎症标志物和肝脏超声成像。
与安慰剂相比,GTE使体重(从29.5±3.8降至27.2±3.2 kg/m,p = 0.03)、BMI(从86±10.5降至80±12.4 kg,p = 0.026)、HOMA - IR(从4.32±2.25降至3.16±1.6,p = 0.0081)、血脂谱(即总胆固醇:从242.5±20.5降至215.4±18.6 mg/dl,p = 0.005;甘油三酯:从175±22.6降至145±18 mg/dl,p = 0.003;低密度脂蛋白胆固醇:从155±12.5降至140±16.7 mg/dl,p = 0.011;高密度脂蛋白胆固醇:从36.8±6.7升至46.4±5.8 mg/dl,p = 0.001)、转氨酶(即谷丙转氨酶:从70.4±15.8降至52.8±12.2 IU/L,p = 0.04;谷草转氨酶:从65.8±12.4降至44.3±8.5 U/L,p = 0.002)和炎症标志物(高敏C反应蛋白:从3.14±0.58降至2.18±0.32,p = 0.023;脂联素:从8.46±1.02升至10.55±3.42μg/ml,p = 0.003)有显著改善。与安慰剂相比,GTE还使超声检查显示的脂肪肝变化消退了67.5%,而安慰剂组仅为25%。
GTE治疗使非糖尿病且血脂异常的非酒精性脂肪性肝病患者的代谢、生化、炎症和放射学参数有显著改善。